文献速递甲状腺核医学肿瘤 PET/CT

靶向Galectin-3在甲状腺原位肿瘤中开辟表征甲状腺癌的新途径

Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer.
PubMed 文献 · J Nucl Med · 2018-10-25

研究在甲状腺原位肿瘤模型中验证靶向Galectin-3(gal-3)作为检测非摄碘性甲状腺癌的特异性方法。乳头状和未分化甲状腺癌细胞均表达gal-3而NIS表达低或缺失,89Zr-DFO-F(ab')2抗gal-3示踪剂高亲和力结合gal-3,PET/CT仅显示肿瘤信号而无肿瘤甲状腺叶无信号。结论表明靶向gal-3可在无放射性碘摄取时特异性显示甲状腺肿瘤。

要点

  • 甲状腺癌细胞系均gal-3阳性而NIS表达低或缺失。
  • 89Zr-DFO-F(ab')2抗gal-3对gal-3高亲和力(Kd约3.9 nM)且免疫活性保留>75%。
  • PET/CT中抗gal-3信号仅见于原位植入肿瘤,无肿瘤甲状腺叶无信号。

核心结论

  • 靶向gal-3可在无放射性碘摄取时实现甲状腺肿瘤的特异性和选择性显像。

研究设计与样本

  • 研究使用乳头状(BcPAP)和未分化(CAL62和FRO82-1)甲状腺癌细胞系,通过Western blot和PCR表征gal-3和NIS表达。
  • 生成89Zr标记的F(ab')2抗gal-3,在二维和三维细胞培养中表征其与125I的 binding。
  • 将甲状腺癌细胞接种至无胸腺裸鼠左甲状腺叶,通过超声和荧光分子断层扫描监测原位肿瘤生长。
  • 进行124I与89Zr-DFO-F(ab')2抗gal-3的头对头PET/CT比较,随后进行生物分布研究和gal-3及NIS表达的免疫组化分析。

主要发现

  • 研究的甲状腺癌细胞均gal-3阳性,而NIS表达低或缺失。
  • 89Zr-DFO-F(ab')2抗gal-3对gal-3高亲和力(解离常数约3.9 nM),在二维细胞培养和肿瘤球中免疫活性保留>75%。
  • 125I在FRO82-1、BcPAP和CAL62中的内化直接依赖于NIS表达,在二维和肿瘤球中均如此。
  • PET/CT显示89Zr-DFO-F(ab')2抗gal-3信号仅与原位植入肿瘤相关,无肿瘤甲状腺叶未检测到信号。
  • 124I PET显示肿瘤浸润叶背景积累(模拟非摄碘性甲状腺癌结节)和正常甲状腺叶高积累,影像数据经示踪剂生物分布和免疫组化证实。

临床怎么用

  • 靶向gal-3的显像方法可在无放射性碘摄取时特异性显示甲状腺肿瘤。
  • 该方法转化至临床有望通过避免使用非特异性显像方法并减少不必要的甲状腺手术来改善患者管理。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preoperative characterization of thyroid nodules is challenging since thyroid scintigraphy fails to distinguish between benign and malignant lesions. Galectin-3 (gal-3) is expressed in well-differentiated and in undifferentiated thyroid cancer types but not in normal thyrocytes and benign thyroid lesions. Herein, we aimed to validate gal-3 targeting as a specific method to detect non-radioiodine-avid thyroid cancer in thyroid orthotopic tumor models. Methods: Papillary (BcPAP) and anaplastic (CAL62 and FRO82-1) thyroid carcinoma cell lines were characterized via Western blot and polymerase chain reaction for gal-3 and sodium-iodide symporter (NIS) expression. An 89Zr-labeled F(ab')2 antigal-3 was generated and characterized for binding versus 125I on 2- and 3-dimensional cell cultures. The thyroid carcinoma cells were inoculated into the left thyroid lobe of athymic nude mice, and the orthotopic tumor growth was monitored via ultrasound and fluorescence molecular tomography. Head-to-head PET/CT comparison of 124I versus 89Zr-deferoxamine (DFO)-F(ab')2 antigal-3 was performed, followed by biodistribution studies and immunohistochemical analysis for gal-3 and NIS expression. Results: The thyroid carcinoma cells investigated were invariably gal-3-positive while presenting low or lost NIS expression. 89Zr-DFO-F(ab')2 antigal-3 tracer showed high affinity to gal-3 (dissociation constant, ∼3.9 nM) and retained immunoreactivity (>75%) on 2-dimensional cell cultures and on tumor spheroids. 125I internalization in FRO82-1, BcPAP, and CAL62 was directly dependent on NIS expression, both in 2-dimensional and tumor spheroids. PET/CT imaging showed 89Zr-DFO-F(ab')2 antigal-3 signal associated with the orthotopically implanted tumors only; no signal was detected in the tumor-free thyroid lobe. Conversely, PET imaging using 124I showed background accumulation in tumor-infiltrated lobe, a condition simulating the presence of non-radioiodine-avid thyroid cancer nodules, and high accumulation in normal thyroid lobe. Imaging data were confirmed by tracer biodistribution studies and immunohistochemistry. Conclusion: A specific and selective visualization of thyroid tumor by targeting gal-3 was demonstrated in the absence of radioiodine uptake. Translation of this method into the clinical setting promises to improve the management of patients by avoiding the use of unspecific imaging methodologies and reducing unnecessary thyroid surgery.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. De Rose F, Braeuer M, Braesch-Andersen S, et al. Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer. J Nucl Med. 2018. PMID: 30361380. doi:10.2967/jnumed.118.219105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。